The Manufacturers Life Insurance Company Increases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

The Manufacturers Life Insurance Company increased its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 107.6% in the 4th quarter, Holdings Channel reports. The firm owned 63,512 shares of the company’s stock after buying an additional 32,917 shares during the period. The Manufacturers Life Insurance Company’s holdings in Janux Therapeutics were worth $3,400,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC grew its position in Janux Therapeutics by 496.5% in the 3rd quarter. Barclays PLC now owns 174,061 shares of the company’s stock worth $7,907,000 after purchasing an additional 144,883 shares during the period. Franklin Resources Inc. increased its position in Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock valued at $937,000 after acquiring an additional 7,442 shares during the last quarter. Avanza Fonder AB bought a new position in Janux Therapeutics in the fourth quarter valued at about $139,000. China Universal Asset Management Co. Ltd. boosted its position in Janux Therapeutics by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock worth $596,000 after purchasing an additional 1,095 shares during the last quarter. Finally, Chicago Capital LLC bought a new stake in shares of Janux Therapeutics during the 4th quarter valued at about $230,000. Institutional investors own 75.39% of the company’s stock.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,640,768.85. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the business’s stock in a transaction on Friday, March 7th. The shares were purchased at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the acquisition, the director now directly owns 10,141,287 shares in the company, valued at $314,582,722.74. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 10,001 shares of company stock worth $313,964. Insiders own 29.40% of the company’s stock.

Janux Therapeutics Trading Down 3.1 %

NASDAQ:JANX opened at $25.56 on Friday. The stock has a 50-day moving average price of $29.27 and a 200 day moving average price of $41.74. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71. The stock has a market capitalization of $1.51 billion, a P/E ratio of -21.85 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.04. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on JANX shares. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Scotiabank reduced their price objective on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. Finally, Wedbush reiterated an “outperform” rating and set a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Janux Therapeutics presently has an average rating of “Buy” and an average target price of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.